From small molecule generics to biosimilars: Technological upgrading and patterns of distinctive learning processes in the Indian pharmaceutical industry

Technology upgrading is a key element of industrialisation and catch-up in developing countries. It is understood that a successful technology upgrading is linked to a coupling of global knowledge flows with local technology effort. However, the changing nature of technology and industries are chall...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Technological forecasting & social change 2019-08, Vol.145, p.370-383
1. Verfasser: Kale, Dinar
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 383
container_issue
container_start_page 370
container_title Technological forecasting & social change
container_volume 145
creator Kale, Dinar
description Technology upgrading is a key element of industrialisation and catch-up in developing countries. It is understood that a successful technology upgrading is linked to a coupling of global knowledge flows with local technology effort. However, the changing nature of technology and industries are challenging existing processes involved in the technology upgrading and creating new patterns of capability development. This raises the questions about factors and processes involved in technology upgrading in firms from developing countries. In this context, this paper explores the movement of Indian pharmaceutical firms from ‘small molecule generics’ towards targeting a new set of opportunities presented by the emergent biosimilar segment in the global generics market. Some leading Indian firms have adopted this technological upgrading route by making a gradual transition towards the development of biosimilar capabilities and using four case studies, this paper reveals internationalisations in form of overseas acquisitions and collaborations with MNCs formed the key basis of technology upgrading strategy for the Indian firms. This paper further shows the hiring of biotech scientists working in advanced countries increasing R&D investment and reorganisation of R&D contributed to managerial upgrading and played a significant role in creating firms' ability to absorb external knowledge. •Study of tech upgrading covering technological intensity with high complexity of knowledge in emerging country firms•Shows internationalisation and collaborations with MNCs as one of the key routes for technological upgrading.•Highlights the critical role of overseas scientists in managerial and scientific capability upgrading in the Indian firms•Reveals significant role of domestic market rather than export market in technological upgrading of Indian firms•Clear value added to tech capability upgrading literature and important implications for other emerging countries firms.
doi_str_mv 10.1016/j.techfore.2018.09.020
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2264589979</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S004016251731123X</els_id><sourcerecordid>2264589979</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-73153b2a1bdfe9c9f5fb27f4bbb7b1f4f45d783f9d7a9636beebb4c4707ab7ba3</originalsourceid><addsrcrecordid>eNqFkctOHDEQRa0IJIbHLyBLrLtj98vtrBIhSJCQ2MDa8qM845Hb7thuJD6Fv6WHSdasanPq3iodhK4pqSmhw_d9XUDvbExQN4SONeE1acg3tKEja6u-J_wEbQjpSEWHpj9D5znvCSGsHYcNer9PccJ5kt7jKXrQiwe8hQDJ6YxLxMrF7CbnZco_8PNaFKKPW6elx8u8TdK4sMUyGDzLUiCFjKPFxuXigi7uFbAHmcIBmlPUkDNk7AIuO8APwTgZ8LyTaZIalvKZ6oJZcklvl-jUSp_h6t-8QC_3d8-3f6rHp98Pt78eK901pFSspX2rGkmVscA1t71VDbOdUoopajvb9YaNreWGST60gwJQqtMdI0yuhGwv0M0xd73v7wK5iH1cUlgrRdMMXT9yzvhKDUdKp5hzAivm5CaZ3gQl4qBB7MV_DeKgQRAuVg3r4s_jIqw_vDpIImsHQYNxCXQRJrqvIj4AIj2aFg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2264589979</pqid></control><display><type>article</type><title>From small molecule generics to biosimilars: Technological upgrading and patterns of distinctive learning processes in the Indian pharmaceutical industry</title><source>Elsevier ScienceDirect Journals Complete</source><source>Sociological Abstracts</source><creator>Kale, Dinar</creator><creatorcontrib>Kale, Dinar</creatorcontrib><description>Technology upgrading is a key element of industrialisation and catch-up in developing countries. It is understood that a successful technology upgrading is linked to a coupling of global knowledge flows with local technology effort. However, the changing nature of technology and industries are challenging existing processes involved in the technology upgrading and creating new patterns of capability development. This raises the questions about factors and processes involved in technology upgrading in firms from developing countries. In this context, this paper explores the movement of Indian pharmaceutical firms from ‘small molecule generics’ towards targeting a new set of opportunities presented by the emergent biosimilar segment in the global generics market. Some leading Indian firms have adopted this technological upgrading route by making a gradual transition towards the development of biosimilar capabilities and using four case studies, this paper reveals internationalisations in form of overseas acquisitions and collaborations with MNCs formed the key basis of technology upgrading strategy for the Indian firms. This paper further shows the hiring of biotech scientists working in advanced countries increasing R&amp;D investment and reorganisation of R&amp;D contributed to managerial upgrading and played a significant role in creating firms' ability to absorb external knowledge. •Study of tech upgrading covering technological intensity with high complexity of knowledge in emerging country firms•Shows internationalisation and collaborations with MNCs as one of the key routes for technological upgrading.•Highlights the critical role of overseas scientists in managerial and scientific capability upgrading in the Indian firms•Reveals significant role of domestic market rather than export market in technological upgrading of Indian firms•Clear value added to tech capability upgrading literature and important implications for other emerging countries firms.</description><identifier>ISSN: 0040-1625</identifier><identifier>EISSN: 1873-5509</identifier><identifier>DOI: 10.1016/j.techfore.2018.09.020</identifier><language>eng</language><publisher>New York: Elsevier Inc</publisher><subject>Biological products ; Biosimilars ; Case studies ; Companies ; Developing countries ; Global local relationship ; Hiring ; India ; Industrialization ; Internationalisation ; LDCs ; Local knowledge ; Pharmaceutical industry ; Pharmaceuticals ; Pharmacy ; R&amp;D ; Research &amp; development ; Technological capabilities ; Technological change ; Technology ; The pharmaceutical industry ; Upgrading</subject><ispartof>Technological forecasting &amp; social change, 2019-08, Vol.145, p.370-383</ispartof><rights>2018</rights><rights>Copyright Elsevier Science Ltd. Aug 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-73153b2a1bdfe9c9f5fb27f4bbb7b1f4f45d783f9d7a9636beebb4c4707ab7ba3</citedby><cites>FETCH-LOGICAL-c420t-73153b2a1bdfe9c9f5fb27f4bbb7b1f4f45d783f9d7a9636beebb4c4707ab7ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.techfore.2018.09.020$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,33772,45993</link.rule.ids></links><search><creatorcontrib>Kale, Dinar</creatorcontrib><title>From small molecule generics to biosimilars: Technological upgrading and patterns of distinctive learning processes in the Indian pharmaceutical industry</title><title>Technological forecasting &amp; social change</title><description>Technology upgrading is a key element of industrialisation and catch-up in developing countries. It is understood that a successful technology upgrading is linked to a coupling of global knowledge flows with local technology effort. However, the changing nature of technology and industries are challenging existing processes involved in the technology upgrading and creating new patterns of capability development. This raises the questions about factors and processes involved in technology upgrading in firms from developing countries. In this context, this paper explores the movement of Indian pharmaceutical firms from ‘small molecule generics’ towards targeting a new set of opportunities presented by the emergent biosimilar segment in the global generics market. Some leading Indian firms have adopted this technological upgrading route by making a gradual transition towards the development of biosimilar capabilities and using four case studies, this paper reveals internationalisations in form of overseas acquisitions and collaborations with MNCs formed the key basis of technology upgrading strategy for the Indian firms. This paper further shows the hiring of biotech scientists working in advanced countries increasing R&amp;D investment and reorganisation of R&amp;D contributed to managerial upgrading and played a significant role in creating firms' ability to absorb external knowledge. •Study of tech upgrading covering technological intensity with high complexity of knowledge in emerging country firms•Shows internationalisation and collaborations with MNCs as one of the key routes for technological upgrading.•Highlights the critical role of overseas scientists in managerial and scientific capability upgrading in the Indian firms•Reveals significant role of domestic market rather than export market in technological upgrading of Indian firms•Clear value added to tech capability upgrading literature and important implications for other emerging countries firms.</description><subject>Biological products</subject><subject>Biosimilars</subject><subject>Case studies</subject><subject>Companies</subject><subject>Developing countries</subject><subject>Global local relationship</subject><subject>Hiring</subject><subject>India</subject><subject>Industrialization</subject><subject>Internationalisation</subject><subject>LDCs</subject><subject>Local knowledge</subject><subject>Pharmaceutical industry</subject><subject>Pharmaceuticals</subject><subject>Pharmacy</subject><subject>R&amp;D</subject><subject>Research &amp; development</subject><subject>Technological capabilities</subject><subject>Technological change</subject><subject>Technology</subject><subject>The pharmaceutical industry</subject><subject>Upgrading</subject><issn>0040-1625</issn><issn>1873-5509</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>BHHNA</sourceid><recordid>eNqFkctOHDEQRa0IJIbHLyBLrLtj98vtrBIhSJCQ2MDa8qM845Hb7thuJD6Fv6WHSdasanPq3iodhK4pqSmhw_d9XUDvbExQN4SONeE1acg3tKEja6u-J_wEbQjpSEWHpj9D5znvCSGsHYcNer9PccJ5kt7jKXrQiwe8hQDJ6YxLxMrF7CbnZco_8PNaFKKPW6elx8u8TdK4sMUyGDzLUiCFjKPFxuXigi7uFbAHmcIBmlPUkDNk7AIuO8APwTgZ8LyTaZIalvKZ6oJZcklvl-jUSp_h6t-8QC_3d8-3f6rHp98Pt78eK901pFSspX2rGkmVscA1t71VDbOdUoopajvb9YaNreWGST60gwJQqtMdI0yuhGwv0M0xd73v7wK5iH1cUlgrRdMMXT9yzvhKDUdKp5hzAivm5CaZ3gQl4qBB7MV_DeKgQRAuVg3r4s_jIqw_vDpIImsHQYNxCXQRJrqvIj4AIj2aFg</recordid><startdate>20190801</startdate><enddate>20190801</enddate><creator>Kale, Dinar</creator><general>Elsevier Inc</general><general>Elsevier Science Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7TB</scope><scope>7U4</scope><scope>8FD</scope><scope>BHHNA</scope><scope>DWI</scope><scope>F28</scope><scope>FR3</scope><scope>JQ2</scope><scope>KR7</scope><scope>WZK</scope></search><sort><creationdate>20190801</creationdate><title>From small molecule generics to biosimilars: Technological upgrading and patterns of distinctive learning processes in the Indian pharmaceutical industry</title><author>Kale, Dinar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-73153b2a1bdfe9c9f5fb27f4bbb7b1f4f45d783f9d7a9636beebb4c4707ab7ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Biological products</topic><topic>Biosimilars</topic><topic>Case studies</topic><topic>Companies</topic><topic>Developing countries</topic><topic>Global local relationship</topic><topic>Hiring</topic><topic>India</topic><topic>Industrialization</topic><topic>Internationalisation</topic><topic>LDCs</topic><topic>Local knowledge</topic><topic>Pharmaceutical industry</topic><topic>Pharmaceuticals</topic><topic>Pharmacy</topic><topic>R&amp;D</topic><topic>Research &amp; development</topic><topic>Technological capabilities</topic><topic>Technological change</topic><topic>Technology</topic><topic>The pharmaceutical industry</topic><topic>Upgrading</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kale, Dinar</creatorcontrib><collection>CrossRef</collection><collection>Mechanical &amp; Transportation Engineering Abstracts</collection><collection>Sociological Abstracts (pre-2017)</collection><collection>Technology Research Database</collection><collection>Sociological Abstracts</collection><collection>Sociological Abstracts</collection><collection>ANTE: Abstracts in New Technology &amp; Engineering</collection><collection>Engineering Research Database</collection><collection>ProQuest Computer Science Collection</collection><collection>Civil Engineering Abstracts</collection><collection>Sociological Abstracts (Ovid)</collection><jtitle>Technological forecasting &amp; social change</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kale, Dinar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>From small molecule generics to biosimilars: Technological upgrading and patterns of distinctive learning processes in the Indian pharmaceutical industry</atitle><jtitle>Technological forecasting &amp; social change</jtitle><date>2019-08-01</date><risdate>2019</risdate><volume>145</volume><spage>370</spage><epage>383</epage><pages>370-383</pages><issn>0040-1625</issn><eissn>1873-5509</eissn><abstract>Technology upgrading is a key element of industrialisation and catch-up in developing countries. It is understood that a successful technology upgrading is linked to a coupling of global knowledge flows with local technology effort. However, the changing nature of technology and industries are challenging existing processes involved in the technology upgrading and creating new patterns of capability development. This raises the questions about factors and processes involved in technology upgrading in firms from developing countries. In this context, this paper explores the movement of Indian pharmaceutical firms from ‘small molecule generics’ towards targeting a new set of opportunities presented by the emergent biosimilar segment in the global generics market. Some leading Indian firms have adopted this technological upgrading route by making a gradual transition towards the development of biosimilar capabilities and using four case studies, this paper reveals internationalisations in form of overseas acquisitions and collaborations with MNCs formed the key basis of technology upgrading strategy for the Indian firms. This paper further shows the hiring of biotech scientists working in advanced countries increasing R&amp;D investment and reorganisation of R&amp;D contributed to managerial upgrading and played a significant role in creating firms' ability to absorb external knowledge. •Study of tech upgrading covering technological intensity with high complexity of knowledge in emerging country firms•Shows internationalisation and collaborations with MNCs as one of the key routes for technological upgrading.•Highlights the critical role of overseas scientists in managerial and scientific capability upgrading in the Indian firms•Reveals significant role of domestic market rather than export market in technological upgrading of Indian firms•Clear value added to tech capability upgrading literature and important implications for other emerging countries firms.</abstract><cop>New York</cop><pub>Elsevier Inc</pub><doi>10.1016/j.techfore.2018.09.020</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0040-1625
ispartof Technological forecasting & social change, 2019-08, Vol.145, p.370-383
issn 0040-1625
1873-5509
language eng
recordid cdi_proquest_journals_2264589979
source Elsevier ScienceDirect Journals Complete; Sociological Abstracts
subjects Biological products
Biosimilars
Case studies
Companies
Developing countries
Global local relationship
Hiring
India
Industrialization
Internationalisation
LDCs
Local knowledge
Pharmaceutical industry
Pharmaceuticals
Pharmacy
R&D
Research & development
Technological capabilities
Technological change
Technology
The pharmaceutical industry
Upgrading
title From small molecule generics to biosimilars: Technological upgrading and patterns of distinctive learning processes in the Indian pharmaceutical industry
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T17%3A03%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=From%20small%20molecule%20generics%20to%20biosimilars:%20Technological%20upgrading%20and%20patterns%20of%20distinctive%20learning%20processes%20in%20the%20Indian%20pharmaceutical%20industry&rft.jtitle=Technological%20forecasting%20&%20social%20change&rft.au=Kale,%20Dinar&rft.date=2019-08-01&rft.volume=145&rft.spage=370&rft.epage=383&rft.pages=370-383&rft.issn=0040-1625&rft.eissn=1873-5509&rft_id=info:doi/10.1016/j.techfore.2018.09.020&rft_dat=%3Cproquest_cross%3E2264589979%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2264589979&rft_id=info:pmid/&rft_els_id=S004016251731123X&rfr_iscdi=true